Long-Acting Injectable PrEP Bringing HIV Prevention to a New Level

Ian Frank, MD & Colleen F. Kelley, MD, MPH

This activity is jointly provided by Global Education Group and Integritas Communications. 


This educational activity is supported by an educational grant from ViiV Healthcare.


Ian Frank, MD
Professor of Medicine
University of Pennsylvania
Associate Chief, Division of Infectious Diseases
Principal Investigator
University of Pennsylvania HIV Clinical Trials Unit
Philadelphia, Pennsylvania

Colleen F. Kelley, MD, MPH
Associate Professor of Medicine
Division of Infectious Diseases
The Hope Clinic of Emory University
Decatur, Georgia

Program Description

Preexposure prophylaxis (PrEP) is an essential tool in the prevention of HIV infection. While oral PrEP medications have been available for several years, there are still challenges with getting PrEP to eligible people and overcoming barriers to adherence. Recently, a long-acting injectable option has become available, which could address some of the challenges that PrEP users experience. Long-Acting Injectable PrEP: Bringing HIV Prevention to a New Level is a multimedia training program consisting of 4 brief circuits that will improve your endurance and build your knowledge about using long-acting injectable PrEP for HIV prevention. Drs. Colleen Kelley and Ian Frank will coach learners through key points and practical considerations for this new type of PrEP.

You will start your workout with an overview of HIV burden, the current status of PrEP in the United States, and the evidence on long-acting injectable PrEP. Next, you will build your knowledge of how to implement long-acting injectable PrEP, from determining eligibility to on-treatment monitoring and navigating transitions. Finally, you will flex your patient communication skills and hear a patient’s perspective on long-acting injectable PrEP.

Target Audience

The educational design of this activity addresses the needs of current PrEP providers and other primary care physicians, nurse practitioners, and physician assistants involved in the prevention of HIV in their patients.

Learning Objectives

After completing this activity, participants will be better prepared to:

  • Describe the mechanisms, efficacy, and safety of long-acting PrEP agents
  • Review protocols for the implementation of long-acting injectable PrEP agents into clinical practice for HIV prevention
  • Develop optimal treatment strategies that address patient-specific factors and preferences

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.75 contact hours (which includes 0.4 hours of pharmacology).

Disclosure of Conflicts of Interest

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the ACCME and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Ian Frank, MD - Consulting Fee: Gilead Sciences, Inc., Merck & Co. Inc., ViiV Healthcare. Contracted Research: GSK, Janssen Pharmacueticals, Moderna, Inc., Pfizer Inc., Sanofi

Colleen F. Kelley, MD, MPH - Contracted Research: Gilead Sciences, Inc., Humanigen, Inc., Moderna, Inc., Novavax, Inc., ViiV Healthcare

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP: Nothing to disclose
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Lauren Sinclair: Nothing to disclose
Susan Daniels: Nothing to disclose
Jim Kappler, PhD: Nothing to disclose
Scott Reeder (Patient Perspective): Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to received credit, participants must complete the following:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Preactivity Questions.
  3. Review the activity content.
  4. Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Global Education Group Contact Information

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

credit amount 0.75

credit type CME/AANP

release 09/22/2022

expiration 09/22/2023

type Webcast